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Abstract
Background: Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is
considered safe. However, minor side effects have included thromboembolism and instant blood-mediated
inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing on
plasmatic coagulation as a secondary hemostasis step detected both procoagulatory and anticoagulatory
activities of MSCs. We now focus on primary hemostasis and analyzed whether MSCs can promote or inhibit
platelet activation.
Methods: Effects of MSCs and MSC supernatant on platelet activation and function were studied using flow
cytometry and further platelet function analyses. MSCs from bone marrow (BM), lipoaspirate (LA) and cord
blood (CB) were compared to human umbilical vein endothelial cells or HeLa tumor cells as inhibitory or
activating cells, respectively.
Results: BM-MSCs and LA-MSCs inhibited activation and aggregation of stimulated platelets independent of
the agonist used. This inhibitory effect was confirmed in diagnostic point-of-care platelet function analyses in
platelet-rich plasma and whole blood. Using inhibitors of the CD39–CD73–adenosine axis, we showed that
adenosine produced by CD73 ectonucleotidase activity was largely responsible for the LA-MSC and BM-MSC
platelet inhibitory action. With CB-MSCs, batch-dependent responses were obvious, with some batches exerting inhibition
and others lacking this effect.
Conclusions: Studies focusing on plasmatic coagulation suggested both procoagulatory and anticoagulatory activities of
MSCs. We now show that MSCs can, dependent on their tissue origin, inhibit platelet activation involving adenosine
converted from adenosine monophosphate by CD73 ectonucleotidase activity. These data may have strong implications
for safety and risk/benefit assessment regarding MSCs from different tissue sources and may help to explain the tissue
protective mode of action of MSCs. The adenosinergic pathway emerges as a key mechanism by which MSCs exert
hemostatic and immunomodulatory functions.
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Background
Due to their numerous and promising therapeutic cap-
acities, mesenchymal stromal cells (MSCs) are already
applied clinically [1]. So far, clinical trials have docu-
mented the safety of MSC applications with rare and
minor adverse events in humans [2–4]. In animals, how-
ever, increased death rates have been observed due to
thromboembolic events after infusion [5–9]. Import-
antly, there has been one report of a patient dying
following a pulmonary embolism, potentially related to
the MSC application [10].
Thromboembolic events may occur via different
mechanisms. First, the relatively large MSCs may be
entrapped in and may subsequently occlude small ves-
sels, particularly lung capillaries [7, 9]. This may explain
why in animals the cell dose and infusion velocity have
been linked to embolic side effects [11]. Second, MSCs
may impact hemostasis and actively promote coagula-
tion through high expression of procoagulant mole-
cules like tissue factor (TF), triggering the clotting
cascade [6, 12–14]. In consequence, clinical trial pro-
tocols have already been modified to add antithrom-
botics such as heparin or hirudin [12, 13, 15–17]. A
recent study suggests selecting for TF-negative MSCs
to avoid thromboembolism and IBMIR [14].
With respect to their procoagulant properties, MSCs
from different tissue sources seem to differ at both ex-
pressional as well as functional levels [14, 18, 19]. In a
mouse model, lipoaspirate-derived MSCs (LA-MSCs)
were associated with higher risks of embolic events in
comparison to bone marrow-derived MSCs (BM-MSCs)
[9]. MSCs derived from placental decidua showed
increased activation of plasmatic clotting compared to
BM-MSCs [13].
In contrast, very few studies have considered the
cellular component of thrombosis/hemostasis. Ob-
served effects have varied from increased platelet
thrombus formation [12, 15, 16] to antithrombotic
properties in vascular grafts [20, 21]. We have there-
fore analyzed the influence of MSCs on platelet acti-
vation. We compared MSCs from different tissue
sources (BM, LA and cord blood), and evaluated
whether conditioned medium or cells stimulate or
inhibit the activation of resting or agonist-induced
activated platelets. Platelet activation and aggregation
was measured using different methods including diag-
nostic point-of-care techniques.
Methods
Blood collection and preparation
Blood was collected with 21-gauge butterfly needles
from antecubital veins into citrate phosphate dextrose
adenine (CPDA)-containing or hirudin-coated tubes.
Donors were volunteer healthy persons giving informed
consent, who had not been taking any platelet inhibiting
medication for at least 2 weeks.
Platelets were deployed for experiments immediately
after collection. Either whole blood or platelet-rich
plasma (PRP) was used, obtained by centrifugation of
whole blood at 100 × g for 10 min. The PRP was diluted
1:1 with phosphate buffered saline (PBS) before subse-
quent use.
MSCs, HUVECs and HeLa cells
Human MSCs from the three different tissue sources—
bone marrow (BM), lipoaspirate (LA) and cord blood
(CB)—as well as human umbilical vein endothelial cells
(HUVECs) were isolated from multiple different donors
and characterized as described previously [22, 23].
Experiments were approved by the Mannheim Ethics
Commission II (vote numbers 2010-262 N-MA,
2009-210 N-MA, 49/05 and 48/05). HeLa tumor cells
were kindly provided by Prof. Ilse Hofmann, DKFZ,
Heidelberg, Germany. HUVECs and HeLa tumor cells
served as controls; endothelial cells have been shown to
inhibit and tumor cells to promote platelet activation
[24, 25].
All cells were stored cryopreserved in fetal bovine
serum (FBS)/10% DMSO and were then thawed and cul-
tivated for at least one passage before use. HUVECs were
cultured in EGM-2 (Lonza, Basel, Switzerland), and MSCs
and HeLa cells in DMEM (Lonza) supplemented with
10% FBS (PromoCell, Heidelberg, Germany), 4 mM glu-
tamine and antibiotics. To standardize conditions for
MSCs, HUVECs and HeLa cells, respectively, cells were
seeded at a defined density in T175 flasks 2 days before
performing the experiments: MSCs at 1 × 106 cells, pas-
sages 3–4 (to test for replicative aging also until passage
6); HUVECs at 2 × 106 cells, passages 3–5; and HeLa cells
at 5 × 106 cells. Immediately before the experiments, the
cells were detached with trypsin–EDTA, washed, counted
and resuspended in PBS. The cell doses (105, 5 × 105,
2.5 × 106 cells/ml) employed for our study were calculated
according to the cell numbers applied clinically [1]. Con-
ditioned medium (CM) was collected 48 h after seeding
106 cells in T175 flasks. Pure culture medium served as a
control.
Flow cytometry
Flow cytometry was performed on a BD FACSCanto™ II
(Becton Dickinson, Heidelberg, Germany). Data were
obtained with BD FACS Diva software and analyzed with
FlowJo software (FlowJo, LLC, Ashland, OR, USA).
Before stimulation, platelets were incubated at room
temperature with respective cells or CM for 10 min in
the presence of the staining antibodies. Following this,
platelets were activated with TRAP-6 (protease-activated
receptor 1 (PAR-1) agonist), ADP (P2Y1, P2Y12 and
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P2X1 receptor agonist) or U46619 (thromboxane A2
(TP) receptor agonist) (all 5 μM; Roche, Mannheim,
Germany) for 10 min. Experiments were performed at
staggered times or samples were fixed directly after the
stimulation period by 0.5% paraformaldehyde and then
analyzed.
Platelets were stained with an antibody panel including
the activation-dependent markers PAC-1-FITC (acti-
vated GPIIb/IIIa (CD41/CD61) complex, clone PAC-1;
Becton Dickinson), CD62P-APC (P-selectin, clone AK-4;
Becton Dickinson) and CD63-PE-Cy7 (LAMP-3, clone
H5C6; Becton Dickinson) and the platelet-specific sur-
face marker CD41-PE (IIb subunit of GPIIb/IIIa com-
plex, clone HIP8; Beckman Coulter, Krefeld, Germany)
[26]. Antibodies had been titrated. A platelet gate was
set according to FSC-PE and at least 10,000 events were
recorded.
To quantify the respective receptor expression by flow
cytometry, cells were stained with anti-CD73 (PE, clone
AD-2; Becton Dickinson), anti-CD39 (PerCP-Cy5.5,
clone TU66; Becton Dickinson) and anti-adenosine A2A
receptor (A2AR, 7F6-G5-A2 Alexa Fluor® 488; Santa
Cruz Biotechnology, Heidelberg, Germany).
Inhibitors
Different mechanisms have been shown to interfere with
platelet activation. To understand which is affected by
MSCs, we used different inhibitors, as specified in the
following [27–29].
CD62P was blocked by the mouse anti-human anti-
body AK-4 (eBioscience, ThermoFisher, San Diego, CA,
USA). PRP 50 μl was preincubated with 1 μg AK-4 or
the respective isotype control for 20 min before adding
the MSCs.
For COX inhibition, MSCs were cultured with indo-
methacin (10 μM; Sigma Aldrich) for 2 days. Two hours
before the experiments the medium was changed and
fresh indomethacin added to the coculture.
CD39 was inhibited by the antagonist sodium
polyoxotungstate (100 and 10 μM POM-1; Tocris,
Wiesbaden-Nordenstadt, Germany), CD73 inhibited by
AMP-CP (100 μM α,β-methyleneadenosine 5′-diphos-
phate; Santa Cruz), adenosine receptors inhibited by caf-
feine (200 μM; Santa Cruz) and A2A adenosine receptor
was inhibited by 25 μM SCH 58261 (Tocris, 25 mM stock
in DMSO, DMSO used as control). Alkaline phosphatase
(ALP) was inhibited by levamisole hydrochloride (100 μM;
Abcam, Cambridge, UK). Adenosine deaminase (ADA)
from calf intestine (2.55 U/ml; Sigma Aldrich) was added
to deaminate adenosine [30, 31]. All inhibitors were prein-
cubated for 10 min with MSCs before adding PRP. Ad-
enosine (1 μM; Santa Cruz) was used as positive control.
For most inhibitors, different dilutions have been tested to
identify the working concentration.
Detection of ectonucleotidase activity
Ectonucleotidase activity was measured in the cells as
described previously [32]. Briefly, cells were seeded at
10,000 cells/cm2 in 24-well plates and then incubated
for 24 h. ATP, ADP and AMP (1 mM; Santa Cruz) were
then added in phosphate-free buffer and incubated for
either 1 h (ATP and ADP) or 30 min (AMP). Super-
natant was harvested for protein quantification (BCA
assay; Thermo Fisher, Waltham, MA, USA), inorganic
phosphate quantification (malachite green assay kit,
according to the manufacturer’s instructions; Sigma
Aldrich) or adenosine detection.
Quantitative determination of adenosine by LC-MS/MS
The samples were separated by HPLC (Agilent 1100,
Waldbronn, Germany) using a LiChrospher 100 RP
C-18, 5 μm column (125 mm × 4 mm) in combination
with a gradient method of acetonitrile and 0.1% acetic
acid at a flow rate of 500 μl/min. Mass spectrometric
analysis was carried out using an API 4000™ quadrupole
mass spectrometer (Applied Biosystems/MDS Sciex, To-
ronto, Canada) equipped with an electrospray ionization
(ESI) source in the positive mode. MS/MS infusion ex-
periments were performed to determine the specific
mass transitions of adenosine (quantifier m/z 268 to m/z
136, qualifiers m/z 268 to m/z 119 and m/z 268 to m/z
92) for multiple reaction monitoring (MRM) analysis.
All quantitative analyses were carried out using a sample
volume of 10 μl containing adenosine-d5 as internal
standard. The adenosine content of the samples was de-
termined by a standard calibration function in the re-
quired concentration range.
Alkaline phosphatase and adenosine deaminase activity
measurement
Both enzymatic activities were measured in cell lysates
with defined cell numbers by fluorometric assay kits ac-
cording to the manufacturer’s instructions (ALP assay
kit ab83371 and ADA assay kit ab204695; both Abcam).
Vasodilator-stimulated phosphoprotein phosphorylation
state
The phosphorylation state of vasodilator-stimulated
phosphoprotein (VASP), indicative for cyclic nucleo-
tide levels in platelets, was measured using cytometric
bead technology (VASPFix; Platelet Solutions, Not-
tingham, UK) [33]. Briefly, PRP was coincubated for
10 min with 10 μM adenosine or 5 × 105 cells/ml,
followed by addition of ADP (5 μM). After 5 min,
5 μl of the platelet suspension was mixed with 25 μl
of VASPFix reagent, vortexed and incubated for 2 h.
The VASP phosphorylation state was assessed by flow
cytometry using an APC (bead) and FITC (VASP-P)
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dot-plot gate, assessing the change in VASP-P-FITC
mean fluorescence intensity (MFI).
Platelet function analyzer
Platelet adhesion, activation and aggregation were
assessed in a system simulating the in-vivo hemodynamics
in the small capillaries (PFA-100; Siemens Healthcare
Diagnostics, Eschborn, Germany). Citrated whole blood
was aspirated at high shear rates though a small aperture
coated with collagen and ADP. The gradual occlusion of
the aperture by adhering platelets was measured as the
closure time. Briefly, 900 μl of citrate-anticoagulated
whole blood (platelet count > 150,000/μl and hematocrit
> 35%) was mixed with either 10 μM adenosine or 5 × 105
cells/ml and incubated for 10 min. The whole blood sus-
pension (800 μl) was added to the analysis cuvettes, the
ADP/collagen measurement was started and the closure
time recorded.
Light transmission aggregometry
The rate and extent of platelet activation, aggregation
and agglutination was measured by light transmission
aggregometry. PRP was stirred in a cuvette at 37 °C and
photometrically monitored. Agonist-induced activation
and aggregation induces a change from light absorbance
to increased transmission (Platelet Aggregation Profiler®,
Model PAP-8E; MöLab GmbH, Langenfeld, Germany).
Briefly, PRP was prepared by centrifugation at 150 × g
for 10 min and then carefully removed. The remaining
blood was centrifuged at 2700 × g for 15 min to obtain
platelet-poor plasma (PPP). The PPP was used to cali-
brate the system to 100% light transmission. Measure-
ments were made on 250 μl aliquots of PRP
preincubated for 10 min with 10 μM adenosine or with
5 × 105 cells/ml at 37 °C in the aggregometry cuvette,
after addition of 5 μM ADP.
Real-time quantitative PCR
Real-time quantitative PCR (RT-qPCR) of procoagulant
and anticoagulant factors was performed as described pre-
viously [34]. The RNeasy Mini Kit® (Qiagen, Hilden,
Germany) was used for mRNA isolation, the Transcriptor
High Fidelity cDNA Synthesis Kit (Roche Diagnostics,
Mannheim, Germany) for cDNA transcription and the
SensiFast™ Probe No-ROX Kit (Bioline, Luckenwalde,
Germany) for PCR. The intron-spanning primers and
probes (Universal Probe Library, Roche, Mannheim,
Germany) presented in Additional file 1: Table S1 were
used with a Light Cycler 480 (Roche). Relative quantifica-
tion was performed using the Ε-method with GAPDH
and SFRS4 as reference genes. The efficiency of all primers
was in the range of 1.9–2.2.
Statistical analysis
For statistical analysis, the degree of platelet activation
was quantified by the mean fluorescence intensity
(MFI) using flow cytometry. For some experiments,
data were normalized to the respective control without
cells/stimulator/inhibitor added. Significance testing
was performed using a paired t test, repeated-measures
one-way ANOVA, one-way or two-way ANOVA
followed by Holmes–Sidak or Dunnett’s test or the
Kruskal–Wallis test for nonparametric data (Sigma Plot
11.0; Systat Software, San Jose, CA, USA; and Graph-
Pad Prism 7; GraphPad Software, La Jolla, USA).
Results
MSC conditioned medium does not affect platelet
activation
To see whether MSCs produce any soluble factors influ-
encing platelet activation, we quantified activation
marker expression on resting (w/o agonist) and ADP or
TRAP-6-stimulated platelets. There was no effect of any
culture medium (CM) on resting platelets (data not
shown). On agonist-stimulated platelets, there was also
no effect of CM on BM-MSCs and LA-MSCs, independ-
ent of the added dose of 2.5–10% (Fig. 1). Low concen-
trations of CB-MSC CM suppressed the activation of
platelets (0.40 ± 0.034 for CD62p and 0.61 ± 0.036 for
PAC-1 at 2.5% CM compared to the control set to 1), but
higher concentrations did not suppress compared to the
control (10% CM, 1.30 ± 0.23 for CD62p and 1.18 ± 0.19
for PAC-1; significant differences between 2.5 and 10%
CM). HUVEC CM had no effect on platelet activation
(1.05 ± 0.04 for CD62p and 0.96 ± 0.04 for PAC-1 at 10%
CM). HeLa CM, however, increased the agonist-induced
activation of platelets dose dependently (from 0.89-fold at
2.5% CM to 4.05-fold at 10% CM for CD62p).
MSCs inhibit agonist-induced platelet activation
Having observed that CM does not affect platelet ac-
tivation, we then assessed the effect in cell–platelet
cocultures. When platelets were agonist stimulated,
all MSCs reduced the degree of platelet activation. All
activation markers assessed were similarly affected
(Fig. 2a). For CB-MSCs, however, donor-specific batch
variation was apparent, with some batches even in-
creasing platelet activation. HUVECs, as expected, re-
duced platelet activation, while HeLa cells had no
significant effect. Next, we tested different MSC concen-
trations in the range of the concentrations employed in
clinical treatments (105, 5 × 105, 2.5 × 106 cells/ml). There
was a clear dose-dependent effect of BM-MSCs (Fig. 2c
for CD62p; other markers not shown). Interestingly, for
LA-MSCs this was not apparent and with higher CB-MSC
numbers the inhibitory effect was reduced, similar to the
CM. HUVECs caused the expected dose-dependent
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inhibition, while HeLa cells had no significant effect at
any concentration.
Next, we checked whether the MSCs activate resting
platelets. BM-MSCs, LA-MSCs and HUVECs did not
activate resting platelets (Fig. 2b, d). Interestingly, 2.5 ×
106 CB-MSCs/ml led to a 5-fold increase in CD62P
expression and an 11-fold increase in PAC-1 binding,
comparable to HeLa cells.
We verified that the inhibitory effect was donor spe-
cific and not affected by cellular aging (passages 3–6;
data not shown), as reported for other MSC properties
[35]. Different culture supplements used to expand
MSCs (FBS, human AB serum or human platelet lysate)
did not affect the inhibitory capacity of either BM-MSCs
or LA-MSCs (data not shown) [36].
Additional experiments were performed: under
shear-flow conditions, BM-MSCs likewise appeared to
reduce the number of platelet aggregates formed on fi-
bronectin (Additional file 2: Figure S1); using imped-
ance aggregometry in whole blood, all cell types
reduced platelet aggregation (multiplate device, Add-
itional file 3: Figure S2); and potential platelet binding
to MSCs was assessed by microscopy and flow cytome-
try. TRAP-6-stimulated platelets formed thrombi. HeLa
cells and also CB-MSCs induced aggregation of acti-
vated and resting platelets (Additional file 4: Figure
S3A–I, p = 0.004 for unstimulated vs stimulated plate-
lets and p = 0.02 for unstimulated platelets vs stimulated
platelets + HeLa cells), whereas BM-MSCs prevented
stimulus-induced platelet aggregation (Additional file 4:
Figure S3I). No platelet binding to any of the cells was ap-
parent using flow cytometry, assessed by gating on MSC
FSC/SSC and then calculating for CD41 positivity (Fig. 3J,
no variance between cells w/o platelets and with unstimu-
lated or stimulated platelets comparing n = 3 biological
replicates for MSC and HUVECs, respectively).
MSCs inhibit platelet activation independent of the
activation pathway, P-selectin and cyclooxygenase
The fact that BM-MSCs and LA-MSCs significantly re-
duced platelet activation prompted the question of
whether specific activation pathways are affected. Using
flow cytometry, we measured three individual activation
markers, CD62p, PAC-1 and CD63, plus three different
platelet agonists, TRAP-6 (chosen for all subsequent
analyses), ADP and U46619. Inhibition was apparent
independent of the anticoagulant (data not shown) and
for all three activation-dependent markers and agonists
(Figs. 1 and 2, Additional file 5: Figure SA, B). Based on
these data we conclude that the MSC-mediated effect is
not directly linked to a specific pathway but interferes
with platelet activation globally.
Fig. 1 Effect of conditioned medium from different cell types on platelet activation. Platelets incubated with either cell culture or conditioned
medium (CM) and then stimulated by TRAP-6. Platelet activation measured by flow cytometry, assessing expression of CD62P, CD63 and PAC-1
binding. a Bone marrow (BM)-MSCs. b Lipoaspirate (LA)-MSCs. c Cord blood (CB)-MSCs. d Human umbilical vein endothelial cells (HUVECs). e HeLa
tumor cells. Scale indicates relative activation marker expression of CM compared to culture medium. n = 3 biological replicates; HeLa cells n = 1, note
different y axis for HeLa cells. *p < 0.05, **p < 0.01, ***p < 0.001. MFI mean fluorescence intensity
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Endothelial progenitor cells have been shown to
suppress platelet activation via CD62p and COX [27,
28]. However, neither the CD62P blocking antibody
AK4 nor the nonselective COX inhibitor indometh-
acin were capable of neutralizing the MSC inhibitory
activity (Additional file 5: Figure S4C, D), although
MSCs express Cox-2 mRNA at highly differing levels
(data not shown).
CD73-converted adenosine is involved in MSC platelet
inhibitory activity
We postulated that adenosine converted by CD73 ectonu-
cleotidase activity may be responsible for the platelet in-
hibition. Adenosine has been shown previously to be
inhibitory in endothelial–platelet interactions, and to con-
tribute to MSC immunomodulatory activity [29, 37–40].
Extracellular ATP metabolism provides the prothrombotic
Fig. 2 Effect of different cell types and dosages on platelet activation and resting platelets in flow cytometry. Platelets incubated with or without
(w/o) indicated cell types. Then platelets either activated by TRAP-6 or remained resting. a, b Influence of 5 × 105 cells/ml on a TRAP-6-induced
platelet activation and b resting platelets. Mean fluorescence intensity (MFI) of different thrombocyte activation markers assessed: CD62P, PAC-1
binding and CD63 (n = 8–17). c, d Dose effect of different cell types on CD62P detection on c TRAP-6-stimulated platelets and d resting platelets
(n = 5–6). Different MFI values of platelets explained by different platelet donors used in individual experiments. In all experiments, paired analysis
against control w/o cells was performed. *p < 0.05, **p < 0.01, ***p < 0.001. BM bone marrow, CB cord blood, HUVEC human umbilical vein endothelial
cell, LA lipoaspirate
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ligands ATP and ADP (released from dense granula upon
platelet activation and hydrolyzed by CD39) and the anti-
thrombotic AMP and adenosine (by CD73 activity) de-
tected by P1 adenosine receptors (on platelets provides
mainly adenosine A2 receptor (A2AR)) [29, 41].
We first checked CD39, CD73 and A2AR expression.
Platelets expressed both CD39 and A2AR at high MFI
values, whereas CD73 was only dimly expressed (Fig. 3a).
In MSCs, in contrast, CD73 was highly expressed, but
CD39 and A2AR only dimly. HUVECs had the highest
CD73 reactivity, with low CD39 and A2AR expression.
To test our hypothesis, we measured platelet activation
and in parallel the adenosine concentration in MSC–
platelet cocultures (Fig. 3b). In the presence of MSCs and
HUVECs, adenosine levels were increased irrespective of
TRAP-6 stimulation. HUVECs, despite a higher CD73 ex-
pression, had adenosine levels only slightly higher than
LA-MSCs and CB-MSCs, with comparable antithrom-
botic activity. BM-MSCs, which showed the highest
adenosine concentrations, exerted the highest inhibitory
activity on platelet activation. These data support our
hypothesis that MSC-generated adenosine conferred anti-
thrombotic activities. In fact, the concentrations measured
in cocultures were exactly in the range of the inhibitory
adenosine concentration, strongest at 10–0.01 μM adeno-
sine for both PRP and whole blood (see Fig. 6a).
To quantify the activity of CD39 and CD73, cells were
incubated with ATP, ADP and AMP and with inhibitors
of the nucleotide degradation cascade (POM-1 for
CD39, AMP-CP for CD73 and SCH 58261 for A2AR).
Fig. 3 Expression and ectonucleotidase activity of CD39, CD73 and A2AR. a Cells stained with respective antibodies and MFI values determined
by flow cytometry. BM-MSCs n = 3, LA-MSCs n = 7, CB-MSCs n = 5, HUVECs, n = 6 each biological replicates; HeLa n = 3 technical replicates; Plt
unst, Plt stim each n = 4 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. b Adenosine concentration (circles, left y axis) measured by mass
spectrometry in supernatants of cell and platelet cocultures, either unstimulated or TRAP-6 stimulated. In parallel, inhibitory effect on TRAP-6-induced
CD62p expression (crosses, right y axis) calculated relative to the TRAP-6 control. BM-MSCs n = 3, LA-MSCs n = 2, CB-MSCs n = 1, HUVECs n = 3 each
biological replicates; HeLa n = 1. ***p < 0.001, ****p < 0.0001. c, d Released phosphate (c) or adenosine (d) indicative of ectonucleotidase activity
determined after incubating cells with ATP, ADP and AMP in presence of respective inhibitors (CD39, POM-1; CD73, AMP-CP; A2AR, SCH 58261). BM-
MSCs, LA-MSCs, CB-MSCs, HUVECs, Plt unst, Plt stim each n = 3 biological replicates; HeLa n = 1. *p < 0.05, ****p < 0.0001. Note different y axis scale for
AMP. ADP adenosine diphosphate, AMP adenosine monophosphate, ATP adenosine triphosphate, BM bone marrow, CB cord blood, HUVEC human
umbilical vein endothelial cell, LA lipoaspirate, n/a not analyzed, Plt stim stimulated platelets, Plt unst unstimulated platelets, w/o without
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The released phosphate and adenosine was measured.
ATP and ADP generated only minor amounts of phos-
phate and adenosine, indicating very low ATP/ADP de-
gradative properties. However, MSCs were able to
catabolize AMP to phosphate and adenosine (Fig. 3b, c),
significantly inhibited by AMP-CP, indicating that CD73
activity is crucial for AMP conversion. Despite the high
expression of CD73 in HUVECs, they showed little
phosphate and adenosine production. In BM-MSCs and
LA-MSCs, POM-1 significantly inhibited phosphate, but
not adenosine generation, suggesting a minor involve-
ment of CD39. Platelets per se, neither unstimulated nor
stimulated, produced detectable amounts of adenosine.
To verify that CD73-converted adenosine regulates
platelet reactivity, we added the aforementioned inhibi-
tors to MSC–platelet cocultures. POM-1 (both 100 and
10 μM) significantly reduced TRAP-induced platelet ac-
tivation (Fig. 4a; ADP and U46619 not shown), support-
ing our notion that CD73-mediated adenosine
generation causes platelet inhibition (Fig. 4b) [42].
AMP-CP and SCH 58261 had no effect on platelet acti-
vation per se. POM-1 did not counteract the
MSC-mediated antithrombotic activity. The CD73 in-
hibitor AMP-CP, however, significantly antagonized the
inhibitory effect of BM-MSCs, LA-MSCs and HUVECs,
supporting our notion that CD73-mediated adenosine
generation causes platelet inhibition (Fig. 4c–f ). In
CB-MSCs, again, data varied with different cell batches.
The adenosine receptor inhibitors, SCH 58261 specific
for A2AR and nonspecific P1 receptor inhibitor caffeine,
partially reversed the inhibitory effects of BM-MSCs and
LA-MSCs, demonstrating that adenosine sensed by ad-
enosine receptors converts the inhibitory signal. The
facts that caffeine exerted a stronger effect in reducing
MSC inhibition while SCH 58261 strongly reduced the
inhibitory activity of adenosine suggest that A2AR is the
main adenosine receptor on platelets, but that in MSC–
platelet cocultures other P1 receptors are predominant,
probably expressed on MSCs [43]. These findings indi-
cate that the CD73–adenosine axis is a key mechanism
in platelet inhibition by MSCs. It was striking that
PAC-1 expression was strongly increased in the presence
of the inhibitors exceeding the expression level of stimu-
lated platelets (set to 1). This suggests that when the in-
hibitory adenosine action is inhibited, MSCs can
accelerate induced platelet activation acting on specific
pathways.
For HUVECs and BM-MSCs there was a large discrep-
ancy between CD73 expression intensity and enzymatic
activity, suggesting that other factors are involved or that
CD73 expression does not correlate to enzymatic activ-
ity. Alkaline phosphatase (ALP) can act synergistically to
CD73 to metabolize AMP to adenosine [31]. Adenosine
deaminase (ADA) activity converts adenosine to inosine,
stopping the inhibitory action of adenosine [30]. HeLa
cells showed high ALP activity (Fig. 5a). BM-MSCs
exerted a highly batch-dependent ALP activity, while the
ALP activity of LA-MSCs, CB-MSCs and HUVECs was
low. ADA activity was comparable for all samples, ex-
cept for LA-MSCs where two out of the three donors
showed high ADA activity. To test for their effects in
MSC–platelet cocultures, we added the ALP inhibitor
levamisole and ADA. Levamisole at a concentration of
1 mM inhibited platelet activation per se, similar to
POM-1. At 100 μM this inhibitory effect was negligible
(Fig. 5c). Levamisole slightly, but not significantly,
reduced the inhibitory effect of all MSCs and HUVECs.
Externally added ADA ameliorated the adenosine action
and significantly reduced the inhibitory effect of
LA-MSCs, probably adding on the ADA activity of
LA-MSCs to achieve adenosine neutralization.
Verification using additional platelet function analyses
To document that MSCs triggered adenosine signaling
in platelets, and that the suppressive strength was rele-
vant not only in PRP but also in whole blood, we
performed further platelet function tests including
point-of-care technologies.
First, we checked the concentration range of adenosine
in PRP and whole blood. In fact, adenosine concentra-
tions obtained in MSC–platelet cocultures were in the
inhibitory range of adenosine in both PRP and whole
blood (Fig. 6a).
Second, the phosphorylation state of vasodilator-stimulated
phosphoprotein (VASP) was assessed in ADP-stimulated
PRP. VASP-P levels are indicative of cAMP levels, known as
master switches of platelet activation and aggregation [33,
41]. Adenosine activates adenylate cyclase, increasing cAMP
levels and VASP phosphorylation, thus inhibiting platelet
aggregation [44]. Indeed, adenosine increased the MFI of
VASP-P, further raised by ADP stimulation (Fig. 6b). Without
ADP stimulation, MSCs and HUVECs led to a slight increase
and to a further rise upon ADP stimulation that was signifi-
cant for BM-MSCs. CB-MSCs clearly split into two clusters,
one inducing little VASP-P elevation after ADP addition
while the other promoted VASP-P levels similar to
BM-MSCs. HeLa cells did not influence VASP-P. These data
support that MSCs induce the same signaling events as
adenosine.
Third, we analyzed the MSC effects on platelet
adhesion, activation and aggregation in whole blood
using the platelet function analyzer (PFA-100), a
well-established diagnostic point-of-care test [45]. As
expected, adenosine prolonged the time needed to form
a platelet plug closing an aperture (Fig. 6c). BM-MSCs,
LA-MSCs and HUVECs likewise delayed platelet func-
tion, while CB-MSCs exerted a minor effect. HeLa cells
repeatedly caused an error in the measurement.
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Fourth, we used light transmission aggregometry
(platelet aggregation profiler, PAP 8E), which distin-
guishes between the different stages of platelet activa-
tion: primary aggregation induced by the added agonist;
secondary aggregation induced by endogenous agonists;
and maximal and final aggregation which may differ
when disintegration of platelet aggregates occurs. The
speed of aggregation is measured as a primary slope.
Area under the curve (AUC) values reflect the entire re-
action cascade. Upon ADP stimulation, adenosine re-
duced the primary aggregation response, the speed and
also the final aggregation compared to the control
(Fig. 6d). The effects of BM-MSCs and LA-MSCs were
similar. CB-MSCs and HUVECs exerted less pro-
nounced platelet inhibition. HeLa cells (n = 1) showed a
similar pattern, possibly related to the platelet donor
(slight inhibitory activity was seen in the corresponding
flow cytometry experiments). Despite the low sample
number, AUC values indicated statistically significant
differences of adenosine; all MSCs and HUVECs re-
duced platelet aggregation. In conclusion, all performed
platelet function analyses confirmed the inhibitory effect
of at least BM-MSCs and LA-MSCs on platelet function
to a similar extent as adenosine.
Gene expression of procoagulant and anticoagulant
factors
In the present study, we identified CD73-generated adeno-
sine as the major mechanism by which MSCs inhibit plate-
let activation. Hemostasis, however, involves at least three
Fig. 4 Blockade of different factors involved in nucleotide degradation cascade. Platelets incubated with cells and either POM-1 to block CD39,
AMP-CP to block CD73, SCH58261 to specifically block adenosine receptor A2A or caffeine as nonspecific P1R inhibitor followed by TRAP-6 activation.
Effects on CD62P expression (a) and PAC-1 binding (b) shown. a Effect of inhibitors on platelets alone (MFI of CD62p and PAC-1), n = 3–18 (n = 3 for
caffeine). *p < 0.05. b Effects induced by adding inhibitors (CD39, POM-1; CD73, AMP-CP; A2AR, SCH 58261; nonspecific P1R, caffeine) in platelet–cell
cocultures. Data normalized against respective control activated by TRAP-6 without cells (dotted line at value 1). BM-MSCs n = 6–11, LA-MSCs n = 5–21,
CB-MSCs n = 5–9, HUVECs n = 3–12 biological replicates; HeLa cells n = 2–9, adenosine n = 4. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. BM bone
marrow, CB cord blood, HUVEC human umbilical vein endothelial cell, LA lipoaspirate, MFI mean fluorescence intensity, w/o without
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steps: vasoconstriction, platelet activation/plug formation
and coagulation. To estimate the potential involvement in
the coagulation cascade and to compare with previously
published data [6, 12–14, 16, 19], we finally assessed the
gene expression of different procoagulatory and anticoagu-
latory genes. Comparing MSCs to endothelial cells—
HUVECs and cord blood-derived endothelial colony form-
ing cells (CB-ECFC) [22]—no differences were observable,
except for TF expression that was apparently higher in all
MSCs (Fig. 7). CB-MSCs compared to CB-ECFCs had a re-
duced expression of plasminogen- activator inhibitor (PAI).
Thus, we conclude that the observed source-specific differ-
ences in platelet reactivity are based on the identified ad-
enosine metabolism rather than on coagulation.
Discussion
With respect to the safety of MSC infusion, our paper
combines a translationally relevant issue with an im-
portant basic research question about the underlying
mechanism. Focusing on the effect of MSCs on plate-
let function, we document that BM-MSCs and
LA-MSCs, and with batch variations also CB-MSCs,
inhibited the agonist-induced activation and aggrega-
tion of platelets—even more than endothelial cells,
well known to regulate platelet reactivity. This inhibi-
tory activity was confirmed to happen in both PRP
and whole blood by applying a variety of platelet
function tests including point-of-care diagnostic tests,
underlining the physiological relevance.
Fig. 5 Alkaline phosphatase and adenosine deaminase activity and function blocking. a Alkaline phosphatase (ALP) and b adenosine deaminase
(ADA) activity in different cell types. Individual biological replicates depicted as dots. c Effects induced by adding ALP inhibitor levamisole or ADA
in platelet–cell cocultures. Data normalized against control activated by TRAP-6 without cells (dotted line at value 1). w/o n = 4–11, BM-MSCs
n = 9, LA-MSCs n = 7–12, CB-MSCs n = 5–9, HUVECs n = 6 biological replicates; HeLa cells n = 3, adenosine n = 4. **p < 0.01. BM bone marrow, CB
cord blood, HUVEC human umbilical vein endothelial cell, LA lipoaspirate, MFI mean fluorescence intensity, w/o without
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We identified the underlying mechanism to involve
CD73-converted adenosine as summarized in Fig. 8.
Activated platelets release ATP and ADP from their
dense granules. Subsequent dephosphorylation of these
agonists to the antagonists AMP by platelet CD39 and
adenosine by MSC CD73 induces P1 receptor signaling
to raise cAMP levels and VASP phosphorylation. This
finally stops the activation cascade and reduces excessive
platelet reactivity.
In fact, we confirmed that adenosine is produced in
MSC–platelet cocultures at levels inhibitory for platelet
function in PRP and whole blood. Using inhibitors of
these enzymes and adenosine receptors, we verified the
crucial role of CD73-converted adenosine. The CD39 in-
hibitor POM-1 had only minor effects on phosphate and
adenosine release but inhibited platelet activation per se,
supporting the CD39 expression and activity in platelets.
In contrast, blockade of CD73 by AMP-CP resulted in a
compensation of MSC inhibitory effects along with a sig-
nificant inhibition of AMP hydrolysis to phosphate and
adenosine, correlating receptor expression to function.
Caffeine, an unspecific adenosine P1 receptor blocker,
and SCH 58261, a specific A2AR antagonist, reduced
the inhibitory effect of MSCs and adenosine. The fact
Fig. 6 Platelet function analyses. Platelet function analyses. a Dose-dependent effect of adenosine on platelet activation (MFI of CD62p and PAC-
1, n=3). b Phosporylation state of vasodilator-stimulated phoshoprotein (VASP), VASP-P MFI levels c Closure time measured as time platelets need
to close an ADP/collagen-coated aperture measured using PFA-100 device, comparing nontreated, adenosine and cell-cocultured whole blood.
***p < 0.001. d Platelet function assessed using light transmission aggregometry (platelet aggregation profiler). Aggregation cascade can be
separated into primary aggregation and slope, final aggregation (all left y axis) and area under the curve (AUC; right y axis) assessing entire
aggregation response. *p ≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. ADP adenosine diphosphate, BM bone marrow, CB cord blood, HUVEC
human umbilical vein endothelial cell, LA lipoaspirate, MFI mean fluorescence intensity, n/a not analyzed, PRP platelet-rich plasma, TRAP thrombin
receptor activator for peptide, WB whole blood, w/o without
Netsch et al. Stem Cell Research & Therapy  (2018) 9:184 Page 11 of 17
that SCH 58261 had a stronger compensatory effect on
adenosine than caffeine, but minor effects in MSC co-
cultures, suggests the involvement of further adenosine
receptor subtypes, nucleotide processing enzymes or nu-
cleoside transporters [31, 40, 43]. It is, however, beyond
the scope of this study to fully dissect the cascade of
purinergic signaling.
Recent studies have documented that MSC CD73-converted
adenosine contributes to the immunomodulatory capacities of
MSCs [37–40]. As in our study, CD39 and CD73 activity may
be influenced by the tissue milieu (e.g. in cancer) and may
require cooperation between different cell types [37, 40, 46].
We show that platelets express both CD39 and A2AR, but
CD73 only weakly. In contrast, MSCs had low CD39 and low
A2AR expression but high CD73 expression. The observed dif-
ferences between BM-MSCs, LA-MSCs and CB-MSCs may
relate to differences in nucleotide hydrolysis activity [32]. In
contrast to our data, other authors detected CD39 expression
in MSCs. Schuler et al. [40, 46] suggest that CD39 expression
is largely influenced by the tissue source and activation state.
Kerkelä et al. [37] observed CD39 expression only in
BM-MSCs, but not in CB-MSCs. LA-MSCs have been tested
negative for CD39 [47]. In addition, MSCs from different mur-
ine tissues have been shown to differ with respect to
Fig. 7 RT-qPCR analysis of prothrombogenic and antithrombogenic genes. Gene expression analyzed in BM n = 3, LA FBS n = 3, LA human AB-
serum n = 2, CB n = 3, HUVECs n = 3, ECFCs n = 3, PBMCs, HepG2 cells and HeLa cells each n = 1. ***p < 0.001. BM bone marrow, CB cord blood,
ECFC endothelial colony forming cell, FBS fetal bovine serum, HUVEC human umbilical vein endothelial cell, LA lipoaspirate, PBMC peripheral
blood mononuclear cell
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ectonucleotidase activity. Murine adipose tissue-derived MSCs
had significantly higher ATP hydrolysis capacity than
BM-MSCs, although the AMP hydrolysis activity was compar-
able. The authors concluded that MSCs exert tissue-specific
roles in regulating the purinergic system [48]. Besides CD39,
ectonucleotide pyrophosphatases/phosphodiesterases (E-NPPs)
could be involved in AMP generation, as shown for HeLa cells
and HUVECs [49].
Our data indicate that CD73 is the key enzyme
involved in antithrombotic adenosine production. Strik-
ingly, the enzymatic activity of HUVECs was low, despite
high CD73 expression. Discrepant expression and activ-
ity data have been described and may be based on point
mutations, splicing alterations or posttranslational modi-
fications [50–53]. Other enzymes such as alkaline phos-
phatase could be involved in nucleotide metabolism
[31]. ALP activity was detected at differing levels in
HeLa cells and MSCs (highest in BM-MSCs, lower in
LA-MSCs and low in both CB-MSCs and HUVECs).
Using levamisole as an ALP inhibitor, the MSC inhibi-
tory activity was reduced. ADA, which degrades adeno-
sine to inosine, was also found to be active in all tested
cells, with quite high activity in LA-MSCs.
Documenting that MSCs induce adenosine signaling,
we verified that VASP phosphorylation was increased,
indicating adenylate cyclase activity and increased cAMP
levels by both MSCs and adenosine. Thus, both
CD39-mediated ADP removal plus CD73-mediated ad-
enosine production modulates platelet activation as
summarized in Fig. 8.
Of high relevance for translation to the clinic, MSCs
exerted their inhibitory effects not only in PRP, but also
in whole blood. In whole blood, leukocytes and erythro-
cytes but also soluble enzymes add to purinergic signal-
ing exerting CD39 and CD73 activity and removing
adenosine by equlibrative nucleoside transporters, re-
spectively [34, 46]. Our data show that adenosine pro-
duced by MSCs can affect platelet activation, despite the
presence of the other cells, to an extent measurable in
diagnostic point-of-care tests.
We observed a common inhibitory activity of MSCs
with similar effects on all markers and agonist stimu-
lations. Only after U46619 stimulation did the inhibi-
tory effect appear to be weaker. It might therefore be
possible that the thromboxane-induced pathway of
platelet activation is less impaired by MSCs. Another
possibility is that U46619 may act directly on MSCs.
Two reports indicate that U46619/thromboxane a(2)
affects MSC differentiation, migration and prolifera-
tion [54, 55].
Fig. 8 Graphical summary of results. Upon agonist-induced platelet activation, ATP and ADP are released. These are converted to AMP by platelet
CD39 activity. AMP is converted to adenosine by MSC-expressed CD73 and to a low extent by alkaline phosphatase. Adenosine signals vial A2AR
and other P1 receptors to raise cAMP levels and to induce VASP phosphorylation. This reduces further platelet activation. Used inhibitors indicated in red.
ADA adenosine deaminase, ADP adenosine diphosphate, ALP alkaline phosphatase, AMP adenosine monophosphate, ATP adenosine triphosphate, TRAP
thrombin receptor activator for peptide, VASP vasodilator-stimulated phosphoprotein
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Importantly, BM-MSCs and LA-MSCs had no effect
on resting platelets. This fits data indicating that
MSC-seeded nanofibrous scaffolds were protected from
platelet adhesion and thrombus formation [21]. Only
some batches of CB-MSCs induced activation marker
expression in resting platelets, similar to the tested
tumor cell line HeLa. The effect of CB-MSCs on resting
platelets may indicate an increased thromboembolic risk
associated with their application, or in a different setting,
a beneficial hemostatic potential [13]. Expression of vari-
ous prothrombotic and antithrombotic genes, however,
was similar for the MSCs from different cellular sources.
These data support our previous findings that CB-MSCs
differ from BM-MSCs and LA-MSCs in several aspects,
namely frequency, differentiation, immunomodulation,
cell marker expression and size [23, 34]. Besides intrin-
sic heterogeneity of MSC preparations, CB appears to
generate at least two distinct MSC-like populations
[23, 56, 57]. It is a matter of future studies to correl-
ate heterogeneity to function.
Interestingly, conditioned MSC medium had no impact
on resting platelets or on the degree of agonist-induced
activation, in contrast to previous reports suggesting a re-
leasable ADPase activity in polymorphonuclear leukocytes
[58]. We conclude that there is no significant production
of any soluble platelet-affecting substances under standard
cell culture conditions, but that the inhibitory activity is
exerted by cell-bound CD73, which metabolizes extracel-
lular AMP to adenosine.
As our major goal is to ensure the safety of MSC infu-
sions, it is imperative to understand the effects of MSCs
on hemostasis after systemic infusion. Hemostasis is a
multistep process involving vasoconstriction, platelet
plug formation and coagulation, and finally fibrinolysis.
MSC involvement has been evaluated previously, focus-
ing on individual steps:
1. MSC conditioned media may promote vasodilation
of pulmonary artery rings [59].
2. TF expression by MSCs may cause
thromboembolism, preventable by use of, or
example, heparin [12, 15].
3. Fibrinolytic activity may regulate migration and
wound healing [60, 61].
As a fourth mechanism by which MSCs can influence
hemostasis, this study shows that MSCs prevent
excessive platelet responsiveness by CD73-converted
adenosine.
The strength of this study is the combination of a
translationally relevant issue with an important basic re-
search question about the underlying mechanism. Our
conclusions build on robust data based on a large num-
ber of MSC and platelet combinations, and MSCs from
three different tissues plus two control cell types, with
the effects demonstrated in both PRP and whole blood
and using a variety of different test systems. The work
opens some new lines of inquiry and questions to be an-
swered in subsequent studies, including tissue-specific
CD73 expression/activity and the interplay of other
cell-bound and soluble nucleotide processing factors.
Conclusions
Our study documents that MSCs do not induce platelet
activation and thereby thrombus formation, but rather
actively inhibit platelet activation by a CD73 activity
generating antithrombotic adenosine. CB-MSCs show
batch-dependent differences. Since CD73 activity has
been further linked to tissue barrier function, adaptation
to ischemic conditions/hypoxia and inflammation, this
mechanism may contribute to the tissue-protective
mode of action of MSCs.
Additional files
Additional file 1: Table S1. Primer and probes used for RT-qPCR ana-
lysis. (DOCX 20 kb)
Additional file 2: Figure S1. Effect of MSCs on platelet adhesion and
aggregation under shear flow conditions. To assess effect of MSCs on
platelet activation under shear flow conditions, we performed
microfluidic experiments using a pneumatically driven channel system
(BioFlux, San Francisco, CA, USA) mounted on an inverted microscope
capable of live cell reflectance interference contrast microscopy (RICM) as
described previously [31]. Briefly, channels were coated with 10 μg/cm2
fibronectin (from human plasma F2006; Sigma Aldrich, St. Louis, MO,
USA). The coated channels were filled with 300 μl of native whole blood
with and without 1.5 × 105 BM-MSCs upon hematocrit adjustment and
perfused with a constant shear stress of 5 dyne/cm2. At indicated points
in time, RICM photographs of channel footprints were taken and analyzed
by counting the number of adherent/aggregated platelets. BM-MSCs n = 3.
(TIF 1135 kb)
Additional file 3: Figure S2. Effect of MSCs on resting and agonist-
induced platelet activation in impedance aggregometry. Impedance
aggregometry experiments conducted using Multiplate® analyzer (Roche
Diagnostics, Mannheim, Germany) [31]. Before stimulation, hirudinized
whole blood samples were preincubated with respective cells or CM for
10 min, a 7-min phase outside the device followed by 3 min incubation
in the aggregometer at 36 °C under stirring. Then 3.3 μM ADP or 6.7 μM
TRAP-6 was added for platelet stimulation. Aggregation assessed for 6 min
and determined as area under the curve (AUC). Whole blood incubated
with two different concentrations of MSCs, HUVECs or HeLa cells. Then
5 μM ADP or TRAP-6 was added to stimulate platelets and impedance was
measured. AUC values normalized to respective control without cells.
n = 2–7. (TIF 784 kb)
Additional file 4: Figure S3. Effect of MSCs on aggregation and
thrombus formation. To assess aggregation and thrombus formation,
fluorescence microscopy experiments were performed. To visualize
platelets, PRP prestained for 30 min with Calcein-AM (1 μg/ml; Merck,
Darmstadt, Germany). PRP with/without respective cells added to 96-well
plates. To observe a cell effect on unstimulated cells, phase-contrast and
fluorescence pictures taken after 10 min (Axio Imager D1, Zeiss AG,
Oberkochen, Germany, with AxioVision software). Platelets then stimu-
lated with 5 μM TRAP-6 for 10 min until taking another series of pictures.
Top row, phase contrast; bottom row, fluorescence microscopy. Represen-
tative pictures from n = 2–3 experiments. A–D 5 μM TRAP-6-stimulated
platelets. A Platelets w/o other cells. Strong aggregation and thrombus
formation visible. B Platelets and HeLa cells. Strong aggregation visible with
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fewer but bigger clots compared to platelets alone. C Platelets and CB-
MSCs. Small aggregates with many single platelets visible. D Platelets and
BM-MSCs. No aggregation visible. E–H Resting platelets. E Platelets w/o
other cells. No aggregation visible. F Platelets and HeLa cells. Strong platelet
aggregation and clotting visible. However, no platelet/HeLa aggregates
formed. G Platelets and CB-MSCs. No clotting appears, but platelets appear
to have undergone morphological changes indicating activation and adhe-
sion. H Platelets and BM-MSCs. Single platelets grouped around BM-MSCs
without aggregation or any evidence for activation. I Platelet aggregate size.
Photomicrographs in A–H analyzed with respect to aggregate size using
ImageJ (n = 3 biological replicates for MSCs and HUVECs, n = 3 technical
replicates for HeLa, different fields of vision analyzed). J Platelet binding to
MSCs. Cells gated on FSC/SSC and assessed for CD41 positivity indicative of
platelet binding. No CD41 positivity detectable in cocultures with unstimu-
lated and stimulated platelets. Representative histograms, mean ± SD CD41
positivity values given relative to w/o platelet control from n = 3 experiments
(technical replicates for HeLa). (TIF 8302 kb)
Additional file 5: Figure S4. Effect of MSCs on platelet activation using
different agonists and pathway inhibitors. A, B Effect of 105 LA-MSCs/ml
on platelet activation after stimulation with different agonists ADP, TRAP-
6 and U46619 (n = 4). Expression of two different activation markers
shown: A CD62P and B PAC-1 binding. *p < 0.05. C, D Effect of AK4 and
indomethacin on platelet inhibition by 5 × 105 BM-MSCs/ml. Platelets
stimulated with TRAP-6. x axis, PAC-1 fluorescence intensity; y, axis, plate-
let count. One of two experiments shown: C AK4 to block CD62P and D
MSC preculture in indomethacin to block COX. (TIF 176 kb)
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